TY  - JOUR
T1  - A Review Study on Chronic Inflammatory Demyelinating Polyneuropathy
A1  - Rayana Alievna Baysurkaeva
A1  - Gadjimurad Zalimkhanovich Baykhanov
A1  - Said-Ibragim Omarovich Gelikhanov
A1  - Vasilisa Romanovna Ostroushko
A1  - Gyunesh Fizulievna Kurbanova
A1  - Eleonora Asefovna Mamalieva
JF  - Archives of Pharmacy Practice
JO  - Arch Pharm Pract
SN  - 2320-5210
Y1  - 2023
VL  - 14
IS  - 4
DO  - 10.51847/JHpJjlQV3E
SP  - 123
EP  - 126
N2  - Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare immune-mediated disease in which an abnormal immune response causes demyelination and damage to the axons of peripheral nerves. This study is a systematic review of the literature. The screening of the abstracts was performed on the abstrackrBeta web-based software platform. The etiology, pathogenesis, modern methods of CIDP treatment, as well as the economic consequences of the spread of the disease, reflected in the scientific literature, are considered. Forty five 45 complete texts and nineteen conference procedures were found on the study of disease transmission n 9, humanistic burden n 7, current treatment n 40, and financial burden n 8 of CIDP. Epidemiological study have appeared the frequency and predominance of 0.2 1.6 and 0.8 8.9 per 100,000, depending on topography and symptomatic criteria. Six main types of therapy have been reported in publications on modern treatment methods: intravenous immunoglobulins, subcutaneous immunoglobulins, corticosteroids, plasmapheresis, immunosuppressants, and immunomodulators. According to the analyzed data, indications for the choice between these methods of treatment, as well as dosage regimens and frequency of use, have not been determined. Thus, CIDP is an autoimmune disease that requires constant monitoring and correction of therapy if necessary. 
UR  - https://archivepp.com/article/a-review-study-on-chronic-inflammatory-demyelinating-polyneuropathy-3c5fkilgtgkkior
ER  -